Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21680652 | 1.00 | TSHR (0.36) | TSHRPKMSMN1; SMN2EPHX1CYP2D6 | |
| SCHEMBL1687826 | 0.83 | TSHR (0.45) | TSHRALDH1A1 | |
| SCHEMBL8156249 | 0.81 | TSHR (0.39) | TSHRPKMSMN1; SMN2EPHX1TNF | |
| SCHEMBL8168454 | 0.81 | TSHR (0.41) | TSHRPKMSMN1; SMN2EPHX1MEN1 | |
| SCHEMBL21707215 | 0.80 | BTK (0.47) | EPHX1KMT2AEPHX2 | |
| SCHEMBL28551553 | 0.80 | BTK (0.47) | EPHX1KMT2AEPHX2 | |
| SCHEMBL4788635 | 0.77 | NPSR1 (0.36) | TSHRSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21079841 | 0.77 | NPSR1 (0.36) | TSHRSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21162002 | 0.77 | PKM (0.36) | TSHRPKMSMN1; SMN2EPHX1CHRNB2 | |
| SCHEMBL25956363 | 0.77 | PKM (0.36) | TSHRPKMSMN1; SMN2EPHX1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048261-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | TSHR 2596/4885PKM 300/4885SMN1; SMN2 653/4885 |
| US-11053250-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | TSHR 2596/4885PKM 300/4885SMN1; SMN2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.